A Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Jun 2017
At a glance
- Drugs NN 9030 (Primary) ; Liraglutide
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 12 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 11 Nov 2016 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.